A Safety Study of SGN-40 in Patients With Non-Hodgkin's Lymphoma
Study Details
Study Description
Brief Summary
This is an open-label, multi-dose, Phase I, dose escalation study to define the safety profile and preliminary anti-tumor activity of SGN-40 in patients with refractory or recurrent non-Hodgkin B-cell lymphomas.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 1 |
Detailed Description
A minimum of 3 patients will be entered into each dose-level cohort for 5 weeks. A dose-escalation schema will be employed in cohorts. The initial dose starts at 1 mg/kg on Day 1 and 4 followed by 2mg/kg on Day 8. Dose escalation will occur on weeks 3-5 with a maximum weekly dose of 8 mg/kg. Patients who meet criteria of at least partial response will be eligible for additional 4 weekly doses at highest dose tolerated.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: 1
|
Drug: SGN-40 (anti-huCD40 mAb)
1 mg/kg IV (in the vein) on Day 1; 1-2 mg/kg IV on Day 4; 2-4 mg/kg IV on Day 8; 3-8 mg/kg on Days 15, 22 and 29.
Other Names:
|
Outcome Measures
Primary Outcome Measures
- Adverse events and lab abnormalities. []
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Patients must have a histological diagnosis of B cell non-Hodgkin's lymphoma, including diffuse large B-cell, mantle cell, follicular, small lymphocytic, and marginal zone lymphoma by the World Health Organization criteria.
-
Patients must have an archived paraffin or fresh tumor specimen available for immunohistologic evaluation of CD40, CD20, & CD79a.
-
Patients must have relapsed lymphoma and must have failed frontline chemotherapy.
-
Patients who have not received autologous stem cell transplant must have refused or be ineligible for it.
-
Patients must have completed radiotherapy, chemotherapy, and/or treatment with investigational anti-cancer agents 4 weeks prior to registration. Patients must have completed any monoclonal antibody treatment, including rituximab, 6 months prior to registration.
-
Patients must have completed autologous bone marrow transplant 4 months prior to registration.
-
Patient must have at least one site of measurable disease defined by unidimensional lesion ≥ 2 cm by conventional CT scan.
-
Patients must have an ECOG performance status ≤ 2 and a life expectancy > 3 months.
-
Patients must have the following required baseline laboratory data:
-
Platelet count ≥ 75,000/mm3,
-
Hemoglobin ≥ 9.0 g/dL,
-
Absolute neutrophil count ≥ 1,250/mm3,
-
ALT/AST ≤ 2.5 times ULN,
-
Total bilirubin ≤ 1.5 times ULN,
-
Creatinine < 1.5 mg/dL,
-
Females of childbearing potential must have a negative serum β-hCG pregnancy test result within 3 days prior to the first dose of SGN-40 and must agree to use an effective contraceptive method during the course of the study and for 6 months following the last dose of study drug.
-
If a deep venous thrombosis or other vascular even has required medical or surgical intervention in the past year, patients must either be on stable dose of anticoagulant therapy for at least 3 weeks or have completed anticoagulant therapy at least 3 months prior to registration with radiographic confirmation that thrombosis is resolved.
-
Patients must be at least 18 years of age.
-
Patients must be available for periodic blood sampling, study-related assessments and management of toxicity at the treating institution.
Exclusion Criteria:
-
Patients with history or clinical evidence of leptomeningeal or central nervous system (CNS) lymphoma.
-
Patients with a documented history within 6 months of registration of a cerebral vascular event, myocardial infarction, deep venous thrombosis or other vascular event that has required medical or surgical intervention. Patients must have completed anticoagulant therapy at least 3 months prior to registration. Prophylactic anticoagulant therapy for indwelling catheters is acceptable.
-
Patients who have received an allogeneic stem cell transplant.
-
Patients who have had major surgery within 4 weeks prior to registration.
-
Patients with a known hypersensitivity to recombinant proteins or any excipient contained in the drug formulation.
-
Patients with a history of another primary malignancy that has not been in remission for at least 5 years (non-melanoma skin cancer and cervical carcinoma in situ on biopsy or a squamous intraepithelial lesion on PAP smear are exempt from the five year limit).
-
Patients with any active systemic viral, bacterial, or fungal infection within four weeks prior to registration.
-
Patients with known positivity for HIV, hepatitis B or hepatitis C infection.
-
Patients with a history of significant chronic or recurrent infections requiring treatment.
-
Patients with a history of migraines or severe headaches requiring medical therapy within 12 months of enrollment.
-
Patients on systemic steroids who have not been on a stable daily dose (not exceeding 10 mg prednisone or equivalent) during 4 weeks prior to the first dose of SGN 40.
-
Patients who are pregnant or breastfeeding.
-
Patients with any serious underlying medical condition that would impair their ability to receive or tolerate the planned treatment.
-
Patients with dementia or altered mental status that would preclude the understanding and/or rendering of informed consent.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | University of Alabama at Birmingham | Birmingham | Alabama | United States | 35294 |
| 2 | Stanford University | Stanford | California | United States | 94305 |
| 3 | University of Miami | Miami | Florida | United States | 33136 |
| 4 | Cornell University | New York | New York | United States | 10029 |
| 5 | University of Texas MD Anderson Cancer Center | Houston | Texas | United States | 77030 |
Sponsors and Collaborators
- Seagen Inc.
- Genentech, Inc.
Investigators
- Study Director: Jonathan Drachman, MD, Seagen Inc.
Study Documents (Full-Text)
None provided.More Information
Additional Information:
Publications
None provided.- SG040-0002